Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
January 07, 2025 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
December 16, 2024 22:25 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Announces Proposed Public Offering
December 16, 2024 17:18 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
December 16, 2024 08:00 ET
|
Reviva Pharmaceuticals
– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and...
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 17:25 ET
|
Reviva Pharmaceuticals
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on...
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
November 12, 2024 08:00 ET
|
Reviva Pharmaceuticals
– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label...
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
November 06, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Participate in the UBS Global Healthcare Conference
October 31, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
October 08, 2024 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 08:30 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...